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Abstract
Background
Immunoassays are crucial in the work-up of patients with suspected heparin-induced throm-
bocytopenia (HIT) and rapid tests have been recently developed. However, comparative
data on diagnostic accuracy, reproducibility, and analytical costs of different immunoassays
in clinical practice are limited.
Methods
Samples of 179 consecutive patients evaluated for suspected HIT in clinical practice using a
polyspecific enzyme-linked immunoabsorbent assay (GTI diagnostics; ELISA) and a rapid
particle gel immunoassay (PaGIA), were additionally analysed with a IgG-specific chemilu-
minescent immunoassay (AcuStar HIT-IgG). Presence of HIT was defined as a positive
functional heparin-induced platelet aggregation test. Diagnostic accuracy was determined
for low, intermediate and high thresholds as previously established (ELISA: optical density
0.4, 1.3, and 2.0 respectively; PaGIA: positive/negative, titre of 4, titre of 32; AcuStar HIT-
IgG: 1.0 U/ml, 2.8, 9.4) and reproducibility was assessed by repeated measurements. Costs
of test determination were calculated taking reagents, controls, and working time of techni-
cians according to Swiss health care system into account.
Results
Data on PaGIA results were available for 171 patients (95.5%), ELISA for 144 patients
(80.4%), and AcuStar HIT-IgG for 179 patients (100%). Sensitivity was above 95% for all
assays at low and intermediate thresholds. Specificity increased with higher thresholds and
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was above 90% for all assays with intermediate and high thresholds. Specificity of AcuStar
HIT-IgG (92.8%; 95% CI 87.7, 96.2) was significantly higher than PaGIA (83.0%; 95% CI
76.3, 88.5) and higher than ELISA (81.8%, 95% CI 74.2, 88.0) at low threshold (p<0.05).
Reproducibility was adequate for all assays. Total costs per test were CHF 51.02 for ELISA,
117.70 for AcuStar HIT-IgG, and 83.13 for PaGIA.
Conclusions
We observed favourable diagnostic accuracy measures and a high reproducibility for PaGIA
and AcuStar HIT-IgG. Implementation into 24-hours-service might improve patient care but
the results must be confirmed in other settings and larger populations as well.
Introduction
The work-up of patients with suspected heparin-induced thrombocytopenia is difficult due to
major practical problems and methodological restrictions [1]. Frequently, suspicion is
expressed at times when haematological consultancy services and sophisticated laboratory
tests are not immediately available: during night-shifts and weekends. However, a decision
whether or not heparin shall be stopped and treatment with alternative anticoagulants started
must be taken rapidly to prevent major complications [2]. Clinical scoring systems such as the
4Ts score are available to guide decision-making at bedside, but rating is difficult in inexperi-
enced hands [1,3–5] and their positive predictive value is too low for diagnosing HIT [6,7].
Functional assays such as the serotonin release assay (SRA), the heparin-induced platelet acti-
vation assay (HIPA) or the heparin-induced platelet aggregation test (PAT) are regarded as
gold-standard for the diagnosis of HIT. However, these tests are time-consuming and available
in very few laboratories only [1]. Thus, physicians mostly rely on immunoassays to establish
the presence of anti-platelet factor 4 (PF4)/heparin antibodies.
The diagnostic accuracy of enzyme-linked immunoassays (ELISA), which are used most
frequently, is well evaluated [8]. However, ELISA results are available once daily at most
because determination is time-consuming and requires a specialized laboratory [1]. Several
rapid immunoassays were developed to overcome this limitation: particle gel immunoassay
(PaGIA), lateral flow immunoassay, latex immunoturbidimetric assay, and chemiluminescent
immunoassay. PaGIA and lateral flow immunoassay can be implemented in routine laborato-
ries, because they do not require specialized analysers or expert knowledge. Chemiluminescent
immunoassay and latex agglutination assay can be easily automated. However, evaluation
studies comparing the diagnostic accuracy, reproducibility and costs of these assays in clinical
practice are very limited, particularly with regard to the Swiss health care system [1,8,9].
To address these issues, we conducted a comprehensive evaluation study comparing accu-
racy, reproducibility, and costs of all commonly used immunoassays in clinical practice.
Methods
Study design and population
To estimate the utility of immunoassays for diagnosis of HIT in clinical practice, we selected a
cohort of patients evaluated for suspected HIT at our institution (Inselspital University Hospi-
tal, University of Bern, Switzerland). To avoid any selection bias, we screened the database for
a period with 190 consecutive patients with residual plasma samples. The following clinical
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data were extracted retrospectively: age, sex, setting (surgery, intensive care unit [ICU], or
internal medicine), as well as results of the 4Ts score. We recorded quantitative results of
ELISA, semi-quantitative results of PaGIA, and PAT if conducted at the time of assessment.
We accepted missing test determinations, because we focused our investigation on real-life
clinical practice. Residual citrated plasma samples were used to additionally perform a recently
developed rapid immunoassay, the IgG-specific chemiluminescent immunoassay (AcuStar
HIT-IgG). The study received approval by the local Ethics review board (Kantonale Ethikkom-
mission Bern; 21.12.2014).
Work-up of patients with suspected HIT in clinical practice
A protocol for management of patients with suspected HIT was implemented in 2004 and
periodically renewed. Haematology consultancy team was informed by attending physicians
or laboratory technicians (HIT test requested). Haematologist contacted attending physicians
to clarify clinical probability, predominantly with the help of the 4Ts score [6]. PaGIA was
conducted in most cases as a preliminary rapid test within few hours, followed by a polyspeci-
fic ELISA in the course of the following week. PAT was conducted as a confirmatory test every
three months at the discretion of the haematology consultant.
Handling of samples and determination of immunoassays
Blood samples were obtained using citrated plastic syringes (Monovette1, Sarstedt, Nu¨m-
brecht, Germany; 1:10 trisodium citrate 0.106 mol/L). Platelet poor plasma was generated by
double centrifugation at 1500 g x 10 min. Aliquots were snap-frozen and stored at -70˚C [7].
PaGIA (DiaMed SA, Cressier sur Morat, Switzerland) was conducted by pipetting 10 μL of
patient plasma to the upper reaction chamber, followed by 50 μL of particle suspension.
Results were recorded after 5 minutes of incubation at room temperature and 10 minutes’ cen-
trifugation with the DiaMed ID-centrifuge. Semi-quantitative results were obtained by titra-
tion studies as previously described [10]. Polyspecific ELISA was determined as reported
elsewhere using a microtiter plate reader, measured at 405 nm (GTI-PF4 Enhanced, Genetic
Testing Institute, Waukesha, WI, USA [7]). AcuStar HIT-IgG (Instrumentation Laboratory,
Bedford, MA, USA) was conducted in batches on a BIO-FLASH1 analyser (Inova Diagnos-
tics, San Diego, California, USA). Samples were thawed rapidly at 37˚C. Assays were calibrated
using AcuStar HIT-IgG calibrator 1+2, and controls were tested before every test run [11].
Results of 4Ts score, ELISA and PAT were not available to the technician conducting AcuStar
HIT assay.
Definition of HIT
HIT was defined as a positive functional assay, the PAT test. Following recent guidelines and
recommendations, PAT was not conducted in a number of patients with a negative ELISA
and/or a negative PaGIA in combination with a low risk/ intermediate risk 4Ts score [7].
These cases were classified as HIT negative. Inconclusive results were excluded as recom-
mended by several authors (n = 8) [12]. We conducted two sensitivity analyses considering
different definitions of HIT to address possible issues regarding PAT as the reference gold
standard: (1) a broad definition of HIT was applied, considering patients with an ELISA result
above OD 2.5 or an PaGIA titre of at least 32 in addition to PAT positive samples, and (2) con-
sidering PAT as definition of HIT only, excluding all patients without PAT results.
We determined a two-point PAT as previously described using a commercially available
light transmission aggregometer APACT 4004 (LABiTec, Ahrensburg, Germany) [13,14].
Patient plasma was tested using platelet rich plasma from 4 selected donors. PAT was classified
Immunoassays for HIT in clinical practice
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as positive if aggregation was more than 50% in at least 2 out of 4 donors with 0.5 U/mL hepa-
rin and suppressed with 100 U/mL heparin. Neither PaGIA nor AcuStar HIT-IgG results were
available to the technician performing PAT and no other result were available to the technician
conducting PaGIA.
Costs
We calculated the analytical cost for determining the individual tests taking the following fac-
tors into account: reagents, controls, calibrators, consumables, and work expended. We
assumed that 5 tests per week are determined, that tests are conducted on different days in
case of PaGIA, AcuStar HIT-IgG, and that ELISA is run once weekly analysing all 5 samples in
one run. In case of PaGIA, we applied 2.3 steps of titration per analysis (average number in
our institution). Costs are based the on Swiss health care system. Labor costs were estimated
according to the average wage of a qualified technician in Switzerland (CHF 42,- per hour).
Statistical analysis
Descriptive statistics was used to characterise the study population. Accuracy was determined
by calculating the sensitivity and specificity as well as likelihood ratios for the individual tests
according to the presence of HIT. Calculations were repeated using two additional definitions
of HIT as sensitivity analysis. Specificities between different thresholds and assays were com-
pared using the z-test. In addition, post-test probabilities of different test results according to
pre-test probability were reported. Calculation of diagnostic accuracy was done at three differ-
ent thresholds; all of them are already established [1,7]. The low threshold corresponds to the
recommendation of the manufacturer. The intermediate and high thresholds were identified
in previous diagnostic accuracy studies with larger patient populations using receiver operat-
ing characteristics analysis [7,15–19]. Thus, an intermediate threshold of PaGIA does not
directly correspond to an intermediate threshold of ELISA. Reproducibility was determined
by calculating coefficients of variation (CV) for within-run repetitions (10 times) as well as
day-to-day (5 times). A CV of 0.1 was set as requirement for imprecision, according to general
principles of ELISA, clinical considerations and previous publications [20–23]. We calculated
a sample size of 190 to demonstrate differences in specificity. We anticipated a frequency of
true-negative values of 85%, considered a difference in specificity of 5% to be clinically relevant
and a fixed a 95% CI. Analyses were performed using the Stata 13.1 statistics software package.
(StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP),
Figs were created using Prism 6 (GraphPad Software, Inc., La Jolla California USA).
Results
Patients
The flow of participants is shown in Fig 1. Residual plasma samples were available in 187 out
of 190 patients. Eight patients were excluded from analysis because of uncertain diagnosis of
HIT. Finally, 179 patients were included for analysis. Among them, AcuStar HIT-IgG was con-
ducted in 179 patients (100%), PaGIA in 171 patients (95.5%), and ELISA in 144 patients
(80.4%). Median age was 70.0 years (inter-quartile range [IQR] 61.3, 76.9), 42.5% were female.
Detailed patient characteristics are shown in Table 1. The clinical setting was surgery in 38.6%
of the cases, internal medicine in 32.4% of the patients, and intensive care unit in 29.1% of the
patients. The clinical risk according to 4Ts score was estimated to be low in 24.6%, intermedi-
ate in 15.6%, and high in 1.7%. The 4Ts score was missing in 104 patients (58.1%) because
samples were received from external hospitals.
Immunoassays for HIT in clinical practice
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Antibody test results
Thirteen patients were classified as HIT-positive because of a positive PAT test. One hundred
and forty-one patients were classified as HIT-negative because of a negative PAT, and 21
patients because of a negative ELISA and/or PaGIA result and a low/intermediate 4Ts score.
Thus, the prevalence of HIT in the present study population was 7%. ELISA was conducted in
144 patients (80.0%), with a major difference between HIT-positive patients (median OD 2.90)
Fig 1. Flow of participants.
https://doi.org/10.1371/journal.pone.0178289.g001
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and HIT-negative patients (median OD 0.17; Table 2; Fig 2). Results were missing in 41
patients (22.9%), mostly because of a negative PaGIA and a low risk 4Ts score. Data on PaGIA
results were available for 171 patients (95.5%), the distribution among HIT-positive and HIT-
negative patients is shown in Table 2 and Fig 2. AcuStar HIT-IgG were conducted in all 179
samples resulting in very low levels in HIT-negative patients and high levels in HIT-positive
samples (Table 2; Fig 2).
Comparative diagnostic accuracy
Quantitative immunoassay results were considerably higher in patients with HIT compared to
patients without HIT in all of the tests (Table 2). The distribution of results in relation to dif-
ferent thresholds of the immunoassays is shown in Fig 2. In the current population, sensitivity
was 100% for all assays at low and intermediate thresholds (Table 3). However, the 95% confi-
dence intervals are wide. At high threshold, sensitivity was 84.6% for the AcuStar HIT-IgG and
58.3% for PaGIA only. Specificity was considerably below 90% at low thresholds for all assays
except for AcuStar HIT-IgG (92.8%; 95% CI 87.7, 96.2). Specificity increased significantly at
intermediate thresholds (PaGIA: 95.6%; 95%CI 91.1, 98.2; ELISA: 96.8; 92.4, 99.2; AcuStar
HIT-IgG: 97.6; 94.0, 99.3). Specificity of AcuStar HIT-IgG was significantly higher than
PaGIA and ELISA at low threshold.
Essentially identical results were observed in first sensitivity analysis, considering PAT as
reference gold standard only (Table A and Table B in S1 File). Sensitivity analysis 2,
Table 1. Patient characteristics according to the presence of HIT.
Characteristics HIT negative HIT positive All samples
Numbers (percent)
Patients 166 (92.7) 13 (7.3) 179 (100)
Age Median (IQR) 70.5 (61.4, 80.0)* 70.9 (65.5, 80.8)+ 70.0 (61.3, 76.9)#
Female sex 74 (44.6) 2 (15.4) 76 (42.5)
Setting
Surgery 61 (36.8) 8 (61.5) 69 (38.6)
ICU 49 (29.5) 3 (23.1) 52 (29.1)
Internal medicine 56 (33.7) 2 (15.4) 58 (32.4)
4T’s score
Low risk 44 (26.5) 0 44 (24.6)
Intermediate risk 22 (13.3) 6 (46.2) 28 (15.6)
High risk 2 (1.2) 1 (7.7) 3 (1.7)
Missing score 98 (59.0) 6 (46.2) 104 (58.1)
* range 22.4, 94.5
+ range 39.6, 82.4
# range 22.4, 94.5
https://doi.org/10.1371/journal.pone.0178289.t001
Table 2. Immunoassay results according to the presence of HIT.
Immunoassay HIT negative HIT positive Available observations
Median (IQR) Numbers (Percent)
PaGIA Titre 0 (0, 0) 64 (16, 128) 172 (96.1)
Polyspecific ELISA (GTI) OD 0.17 (0.11, 0.28) 2.90 (2.58, 3.00) 144 (80.4)
AcuStar HIT-IgG U/ml 0.02 (0.00, 0.10) 20.44 (14.55, 24.71) 179 (100)
https://doi.org/10.1371/journal.pone.0178289.t002
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considering a broad definition of HIT revealed lower numbers for sensitivity and a comparable
specificity for all of the assays. However, sensitivity was above 90% at low thresholds as well.
Fig 2. Accuracy of different immunoassays for diagnosis of HIT in clinical practice. Distribution of quantitative results according to presence of HIT
(positive or negative heparin-induced platelet aggregation test [PAT] respectively and clinical criteria) is shown for different thresholds of the test. (A)
enzyme-linked immunoassay (ELISA), (B) particle gel immunoassay (PaGIA), and (C) IgG-specific chemiluminescent immunoassay (AcuStar HIT-IgG).
https://doi.org/10.1371/journal.pone.0178289.g002
Table 3. Diagnostic accuracy of immunoassays according to PAT result.
Immunoassay TP FN FP TN Sensitivity Specificity Difference in specificity Likelihood ratio
Percent
(95%CI)
p<0.05
compared to
Positive
(95%CI)
Negative
(95%CI)
PaGIA
Low threshold
(Positive/ negative)
12 0 27 132 100.0
(73.5, 100.0)
83.0
(76.3, 88.5))
AcuStar HIT-IgG 5.9
(4.2, 8.3)
0.0
Intermediate threshold
(Titre of 4)
12 0 7 152 100.0
(73.5, 100.0)
95.6¶
(91.1, 98.2)
22.7
(11.0, 46.9)
0.0
High threshold
(Titre of 32)
12 5 0 159 58.3
(27.7, 84.8)
100.0#
(97.7, 100.0)
>1000 0.29
Polyspecific ELISA (GTI)
Low threshold
(OD 0.4)
12 0 24 108 100.0
(73.5, 100.0)
81.8
(74.2, 88.0)
AcuStar HIT-IgG 5.5
(3.8, 7.9)
0.0
Intermediate threshold
(OD 1.3)
12 0 4 128 100.0
(73.5, 100.0)
96.8¶
(92.4, 99.2)
33.0
(12.6, 86.6)
0.0
High threshold
(OD 2.0)
12 0 3 132 100.0
(73.5, 100.0)
97.7
(93.5, 99.5)
44.0
(14.4, 130.0)
0.0
AcuStar HIT-IgG
Low threshold
(1.0 U/ml)
13 0 12 154 100.0
(75.3, 100.0)
92.8
(87.7, 96.2)
PaGIA, ELISA 13.8
(8.0, 23.9)
0.0
Intermediate threshold
(2.8 U/ml)
13 0 4 162 100.0
(75.3, 100.0)
97.6¶
(94.0, 99.3)
41.5
(15.8, 110.0)
0.0
High threshold
(9.4 U/ml)
11 2 1 165 84.6
(54.6, 98.1)
99.4
(96.7, 100.0)
140.5
(19.6, 1000.0)
0.15
(0.04, 0.55)
TP, true positives; FN, false negatives; FP, false positives; TN, true negatives
¶ p<0.05 for difference in specificity compared to low threshold
# p<0.05 for difference in specificity compared to intermediate threshold
https://doi.org/10.1371/journal.pone.0178289.t003
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Reproducibility
Within-run imprecision was within predefined limits for all assays (CV<0.1). A CV of 0.04
was determined for ELISA, and 0.03 for AcuStar HIT-IgG. Antibody titre was identical in 9
out of 10 PaGIA measurements (one replicate with a titre of 4 instead of 2).
Day-to-day variation was within the predefined limits as well (CV0.1). For ELISA, CV
was 0.07, and for AcuStar IgG 0.03. Four out of 5 PaGIA titres were identical (a titre of 4
instead of 2 was seen in one sample) confirming previous results [22].
Costs
We calculated total costs per test for the individual assays as follows: CHF 51.02 for ELISA,
CHF 117.70 for AcuStar HIT-IgG, and 83.13 for PaGIA. In case of ELISA, reagents summed
up to CHF 26.10 per sample (including controls and calibrators), consumables to CHF 1.90,
and average wage of CHF 24.5 (175 minutes of work expended). For PaGIA, reagents costs
CHF 65.19, consumables 0.44, and wage CHF 17.50 (25 minutes). Costs of AcuStar HIT-IgG
were CHF 106.20 for reagents, CHF 1.00 for consumables, and CHF 10.50 for wages (15
minutes).
Discussion
As observed in clinical practice, all immunoassays demonstrated adequate diagnostic accuracy
measures at intermediate thresholds; sensitivity was above 95% and specificity above 90%. In
general, specificity was higher with AcuStar HIT-IgG and lower at low thresholds for all assays.
A good reproducibility was shown for all tests. Relevant differences exist with regard to analyti-
cal costs in the Swiss health care system.
Even though this study was conducted in clinical practice, our results are in-line with previ-
ous publications. First polyspecific ELISA were developed in the nineties, and a number of
studies evaluated their diagnostic accuracy [8]. A recent meta-analysis estimated the pooled
sensitivity to be 96.7% at low threshold and 98.4% at intermediate threshold [8] (specificity
86.8% and 94.9% respectively). In the same meta-analysis, diagnostic accuracy of PaGIA was
calculated to be 96.5% (low threshold), and 98.9% (intermediate threshold). Specificity of
PaGIA was 93.7% and 95.9% respectively. Specificity of PaGIA was considerably lower in our
investigation, probably due to a limited precision (restricted number of patients) or some
inconsistencies of test determination in clinical practice. Fewer studies focused on chemilumi-
nescent immunoassay [11,15,16,24–26], pooled data are available from the same meta-analysis
(sensitivity at low/ intermediate thresholds for AcuStar HIT-IgG 98.9%/ 78.6%; specificity of
AcuStar HIT-IgG 94.9%/ 98.7%). In our data, sensitivity was higher at intermediate thresholds,
most likely because of a limited number of HIT-positive patients.
Most previous data on reproducibility originate from a North American proficiency testing
program [23]. CV was 0.29 for a polyspecific ELISA (GTI). Our data, showing much lower var-
iation, suggest relevant variation in laboratory procedures as a source for this variability. A
good reproducibility was shown in one study for PaGIA [10,22] and in another for chemilumi-
nescent immunoassay as well [11].
Costs of “rapid” tests, PaGIA and chemiluminescent immunoassays were higher compared
to the ELISA assay. However, rapid immunoassays can be conducted in a 24 hours service,
reducing the time span between suspicion of HIT and antibody testing from several days to
few hours. A recent published budget model estimated that this might save a relevant amount
of anticoagulant treatment costs, by far outweighing the higher analytical cost [9].
The strengths of our study are that we included consecutive patients evaluated for HIT in
clinical practice. Thus, our results are applicable to real-life practice. In addition, we evaluated
Immunoassays for HIT in clinical practice
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a number of important criteria that determine the utility in clinical practice in a joint assess-
ment: accuracy, reproducibility, as well as costs. Furthermore, we directly compared com-
monly used immunoassays. Even more, we applied the costs of the Swiss health care system,
providing recommendations for Swiss physicians and laboratory managers in particular.
Our study has several important limitations. First, the number of observations and the
number of true HIT cases is limited. This is reflected by wide confidence intervals and a sensi-
tivity of 100%, which is higher than previously estimated [8]. However, a high sensitivity of all
assays is already known and our primary outcome was specificity. In addition, our results
obtained in clinical practice confirm previous studies conducted in more rigorous settings and
this is the most important message of the present investigation [8,27]. Second, a relevant num-
ber of measurements are missing and some patients had to be excluded due to missing plasma
samples (n = 3) or PAT results (n = 8). This might lead to selection of patients and affect the
internal validity of the study. However, we focused on a high applicability to clinical practice,
which is an important issue in diagnostic accuracy studies as well [28]. In addition, exclusion
of patients with inconclusive reference standard results is recommended by other authors [12].
Third, PAT as reference standard is criticized because of a limited sensitivity [1]. We con-
ducted a sensitivity analysis to address this issue by applying a broad definition of HIT, consid-
ering all patients as HIT positive with an ELISA OD above 2.0 and/ or an PaGIA titre of at
least 8 (Table C and D of S1 File). Sensitivity was more limited for all assays but still similar to
previous publications [8] with a comparable pattern between assays and thresholds. Finally,
our analysis of cost was based on the Swiss health care system limiting the applicability to dif-
ferent countries. Moreover, we did not take the analyzer for determination of chemilumines-
cent immunoassay into account, assuming that this test will only be considered if a respective
analyzer by Instrumentation Laboratory, is already implemented for other purposes. Another
limitation is that we conducted chemiluminescent immunoassays retrospectively on stored
samples. Thus, our investigation might not reflect inconsistencies of test determination in
real-life practice.
Our data suggest that rapid immunoassays have accuracy and reproducibility properties
that are at least as good as an ELISA assay. Furthermore, they have the potential to relevantly
improve patient care due to a shorter turn-around time. Not only that unnecessary switching
to alternative anticoagulants will be avoided, but the risk of thromboembolic complications
while waiting for laboratory results will be prevented. Even more, they offer the potential of
relevantly saving treatment-related health care costs [9]. The easy handling of PaGIA without
the need for specialized knowledge or analyzers facilitates the implementation of a 24-hours-
service even in small to middle-sized medical laboratories. In contrast, chemiluminescent
immunoassays are fully automatable. We suggest applying intermediate thresholds at least for
polyspecific assays in order to improve specificity. However, we do not recommend to imple-
ment an intermediate threshold for AcuStar HIT-IgG because sensitivity was limited in other
studies [8].
Our study was restricted on the presence of HIT as the only clinical outcome. Future pro-
spective multicenter studies might focus on clinical outcomes such as thromboembolic, bleed-
ing complications, and deaths as well. In addition, evaluation studies are needed in order to
investigate the diagnostic accuracy and clinical outcomes of complete diagnostic algorithms
comprising clinical scoring systems immunoassays as well.
In conclusion, rapid immunoassays for diagnosis of HIT have favorable characteristics in
terms of diagnostic accuracy and reproducibility in clinical practice. The implementation of
24-hour service using these tests might not only improve care in patients with suspected HIT
but has the potential to save treatment-related health care costs.
Immunoassays for HIT in clinical practice
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